Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity

Journal of Hepatology

Volumn 66, Issue 5, 2017, Pages 952-961

  Moeini, Agrin ^a,b   Sia, Daniela ^b   Zhang, Zhongyang ^b   Camprecios, Genis ^b   Stueck, Ashley ^b   Dong, Hui ^a   Montal, Robert ^a   Torrens, Laura ^a   Martinez Quetglas, Iris ^a   Fiel, M Isabel ^b   Hao, Ke ^b   Villanueva, Augusto ^b   Thung, Swan N ^b   Schwartz, Myron E ^b   Llovet, Josep M ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Liver cancer; Molecular subclass; Progenitor like origin; TGF signaling

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; APOLIPOPROTEIN B; BILIRUBIN; CA 19-9 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOKERATIN 19; CYTOKERATIN 7; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HEPATOCYTE NUCLEAR FACTOR 3GAMMA; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SOMATOMEDIN; SPALTLIKE TRANSCRIPTION FACTOR 4; STAT3 PROTEIN; STAT5 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER STEM CELL; CHOLANGIOLOCELLULAR CARCINOMA; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MUTATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WHOLE EXOME SEQUENCING; BILE DUCT TUMOR; CLASSIFICATION; GENETICS; LIVER TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CHROMOSOMAL INSTABILITY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 85013795906     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.01.010     Document Type: Article

References (49)

1. [1] Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., et al. Hepatocellular carcinoma. Nat Rev Dis Prim, 2, 2016, 16018.
2. [2] Theise, N.D., Nakashima, O., Park, Y.N., Nakanuma, Y., Combined hepatocellular-cholangiocarcinoma. Bosman, F.T., Carneiro, F., Hruban, R.H., Theise, N.D., (eds.) WHO classification of tumours of the digestive system, 4th ed., 2010, IARC, Lyons, 225–227.
3. [3] Jarnagin, W.R., Weber, S., Tickoo, S.K., Koea, J.B., Obiekwe, S., Fong, Y., et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94 (2002), 2040–2046.
4. [4] Wachtel, M.S., Zhang, Y., Xu, T., Chiriva-Internati, M., Frezza, E.E., Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol 1 (2008), 43–47.
5. [5] Sempoux, C., Fan, C., Singh, P., Obeidat, K., Roayaie, S., Schwartz, M., et al. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis 31 (2011), 104–110.
6. [6] Lee, J.-H., Chung, G.E., Yu, S.J., Hwang, S.Y., Kim, J.S., Kim, H.Y., et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 45 (2011), 69–75.
7. [7] Yin, X., Zhang, B.-H., Qiu, S.-J., Ren, Z.-G., Zhou, J., Chen, X.-H., et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19 (2012), 2869–2876.
8. [8] Lee, W.-S., Lee, K.-W., Heo, J.-S., Kim, S.-J., Choi, S.-H., Kim, Y.-I., et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36 (2006), 892–897.
9. [9] Sasaki, M., Sato, H., Kakuda, Y., Sato, Y., Choi, J.H., Nakanuma, Y., Clinicopathological significance of “subtypes with stem-cell feature” in combined hepatocellular-cholangiocarcinoma. Liver Int 35 (2015), 1024–1035.
10. [10] Ikeda, H., Harada, K., Sato, Y., Sasaki, M., Yoneda, N., Kitamura, S., et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol 140 (2013), 329–340.
11. [11] Komuta, M., Spee, B., Vander Borght, S., De Vos, R., Verslype, C., Aerts, R., et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47 (2008), 1544–1556.
12. [12] Oishi, N., Kumar, M.R., Roessler, S., Ji, J., Forgues, M., Budhu, A., et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and EMT in intrahepatic cholangiocarcinoma. Hepatology 56 (2012), 1792–1803.
13. [13] Coulouarn, C., Cavard, C., Rubbia-Brandt, L., Audebourg, A., Dumont, F., Jacques, S., et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis 33 (2012), 1791–1796.
14. [14] Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun, 6, 2015, 6120.
15. [15] Woo, H.G., Lee, J.H., Yoon, J.H., Kim, C.Y., Lee, H.S., Jang, J.J., et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 70 (2010), 3034–3041.
16. [16] Cazals-Hatem, D., Rebouissou, S., Bioulac-Sage, P., Bluteau, O., Blanché, H., Franco, D., et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 41 (2004), 292–298.
17. [17] Villanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140 (2011), 1501–1512, e2.
18. [18] Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144 (2013), 829–840.
19. [19] Saha, S.K., Parachoniak, C.A., Ghanta, K.S., Fitamant, J., Ross, K.N., Najem, M.S., et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513 (2014), 110–114.
20. [20] Hoshida, Y., Nijman, S.M.B., Kobayashi, M., Chan, J.A., Brunet, J.-P.P., Chiang, D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69 (2009), 7385–7392.
21. [21] Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47 (2008), 2059–2067.
22. [22] Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
23. [23] Yamashita, T., Forgues, M., Wang, W., Kim, J.W., Ye, Q., Jia, H., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 (2008), 1451–1461.
24. [24] Chiang, D.Y.Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008), 6779–6788.
25. [25] Boyault, S., Rickman, D.S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007), 42–52.
26. [26] Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D.F., Sun, Z., Roskams, T., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 (2004), 667–676.
27. [27] Tovar, V., Alsinet, C., Villanueva, A., Hoshida, Y., Chiang, D.Y.Y., Solé, M., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52 (2010), 550–559.
28. [28] Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143 (2012), 1660–1669, e7.
29. [29] Andersen, J.B., Spee, B., Blechacz, B.R., Avital, I., Komuta, M., Barbour, A., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142 (2012), 1021–1031, e15.
30. [30] Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun, 6, 2015, 6087.
31. [31] Ong, C.K., Subimerb, C., Pairojkul, C., Wongkham, S., Cutcutache, I., Yu, W., et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 44 (2012), 690–693.
32. [32] Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47 (2015), 505–511.
33. [33] Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46 (2014), 1267–1273.
34. [34] Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007), 153–158.
35. [35] Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
36. [36] Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
37. [37] Hoshida, Y., Brunet, J.-P., Tamayo, P., Golub, T.R., Mesirov, J.P., Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One, 2, 2007, e1195.
38. [38] Komuta, M., Govaere, O., Vandecaveye, V., Akiba, J., Van Steenbergen, W., Verslype, C., et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 55 (2012), 1876–1888.
39. [39] Akiba, J., Nakashima, O., Hattori, S., Tanikawa, K., Takenaka, M., Nakayama, M., et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 37 (2013), 496–505.
40. [40] Massagué, J., TGFbeta in Cancer. Cell 134 (2008), 215–230.
41. [41] Wu, K., Ding, J., Chen, C., Sun, W., Ning, B.-F., Wen, W., et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 56 (2012), 2255–2267.
42. [42] Karkampouna, S., Ten Dijke, P., Dooley, S., Julio, M.K., TGFβ signaling in liver regeneration. Curr Pharm Des 18 (2012), 4103–4113.
43. [43] Chen, Y., Huang, Y., Reiberger, T., Duyverman, A.M., Huang, P., Samuel, R., et al. Differential effects of sorafenib on liver vs. tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59 (2014), 1435–1447.
44. [44] Chew, V., Chen, J., Lee, D., Loh, E., Lee, J., Lim, K.H., et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61 (2012), 427–438.
45. [45] Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25 (2007), 2586–2593.
46. [46] Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
47. [47] Yong, K.J., Gao, C., Lim, J.S.J., Yan, B., Yang, H., Dimitrov, T., et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368 (2013), 2266–2276.
48. [48] Fujii, H., Zhu, X.G., Matsumoto, T., Inagaki, M., Tokusashi, Y., Miyokawa, N., et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol 31 (2000), 1011–1017.
49. [49] Moeini, A., Sia, D., Bardeesy, N., Mazzaferro, V., Llovet, J.M., Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res 22 (2016), 291–300.